Roughly 10% of the population carries these variants, which appear to cause a mysterious form of "GLP-1 resistance." In several clinical trials, carriers were significantly less likely to reach healthy blood sugar targets while taking GLP-1 medications
It distinguishes carefully between well-supported observations and areas where the evidence is thin or absent
MHRA Updated Semaglutide Guidance Including NAION Warning (GOV.UK, February 2026) 3
Heart rate increases of 2 to 4 beats per minute have been observed with both drugs in clinical trials
Six InBody parameters form the GLP-1 monitoring panel : SMM, BFM, VFL, Phase Angle, BMR, and ECW/TBW ratio together provide a complete picture of whether semaglutide therapy is producing quality fat loss or causing hidden metabolic harm
BPC-157 for Active Lifestyles If you love staying active, you know that recovery is just as important as the activity itself